Clinical Trial: NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Official Title
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
Conditions
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Intervention / Treatment
- Biological: Zilovertamab vedotin
Other Study ID Numbers
- 2140-004
- MK-2140-004
- 2022-501243-33-00
- U1111-1279-9073
- 2021-003397-32
Start Date (Actual)
2022-01-08
Primary Completion Date (Actual)
2026-04-21
Study Completion Date (Actual)
2026-04-21
Enrollment (Actual)
140
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Official Title
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
Conditions
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Intervention / Treatment
- Biological: Zilovertamab vedotin
Other Study ID Numbers
- 2140-004
- MK-2140-004
- 2022-501243-33-00
- U1111-1279-9073
- 2021-003397-32
Start Date (Actual)
2022-01-08
Primary Completion Date (Actual)
2026-04-21
Study Completion Date (Actual)
2026-04-21
Enrollment (Actual)
140
Study Type
Interventional
Phase
Phase 2